The importance of sterility testing
The user’s guide to regulatory expectations, the testing process, what to do in the event of test failure, and more.
Cherwell Laboratories, specialist suppliers of products for environmental monitoring and process validation, has published an eBook titled, “Failure is not an option: Why sterility testing is so important”, which is available to download from Cherwell’s website.
The guide offers a full overview of sterility testing including why the sterility test is such an important requirement for the manufacture of sterile products. It provides some practical steps that will help ensure the standards as set out by the European Pharmacopoeia and GMP are met. The eBook also addresses the role of environmental monitoring programs and how these are critical to successful sterility testing, product quality and business reputation.
Andy Whittard, Cherwell Laboratories’ Managing Director comments: “While we recognise that sterility testing is a critical step in ensuring that pharmaceutical products are safe for human use, we also all know that the test is not perfect. Therefore, we have put together this eBook to offer some guidance and practical steps to overcome the challenges involved with sterility testing. Our guide will help the reader mitigate the risk of sterility test failure for their facility by using better processes and continuous environmental monitoring methods.”
Topics covered within the eBook include the sterility test principle; what the expectations are within the pharmacopoeia and GMP; key considerations in the sterility testing process; how to tackle a sterility test failure and practical steps to minimise risk of contamination.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.